Nov 11 2023
Recombinant ADAMTS13 Therapeutic
On November 9, 2023, Takeda’s recombinant ADAMTS13 received FDA approval for the care of congenital thrombotic thrombocytopenic purpura [cTTP]. Click here for their news release. Click here for the US Thrombotic Microangiopathy Alliance for more cTTP information and information on the family of TMAs.
read more